Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search Stock, IPO, MF
Open in App
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
Charts & Report
Charts and Graphs
Stock Report Pdf
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
IPO
Alerts
(1)
About
Alivus Life Sciences Ltd.
NSE: ALIVUS
|
BSE: 543322
|
ISIN: INE03Q201024
|
Industry: Pharmaceuticals
|
Strong Performer, Getting Expensive
1370.6000
22.80
(
1.69
%)
NSE
Sep 16, 2026
15:31 PM
67.35% Gain from 52W Low
Volume:
153.2K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Alivus Life Sciences Ltd.
26 Aug 2024
1370.60
1.69%
Glenmark Life Science
Buy:
Alivus Life Sciences Ltd.
by
ICICI Direct
Target: 1295
Target
ICICI Direct
Alivus Life Sciences has gained
30.38%
in the last 3 Months
More from Alivus Life Sciences Ltd.
Recommended
Better than Apple: The best NSE IPO trades happened before most of us had demat accounts
|
16 Sep 2026, 07:35PM
Market closes higher, led by gains in FMCG and PSU banking stocks
Trendlyne Marketwatch |
16 Sep 2026, 03:58PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
|
27 Jul 2021